med fusion, an integrated Molecular Center of Excellence and clinical trials service organization headquartered in Lewisville, Texas, has released its solid tumor molecular profiling testing services (SEQ) enhanced by next generation sequencing (NGS) technology. The introduction of NGS will further enable physicians to interrogate their patient’s tumor at the molecular level in order to develop a personalized treatment plan according to the genetic makeup of their specific tumor.
With integrated and comprehensive testing services, med fusion offers both disease-specific panels (LUNGSEQ, COLONSEQ, COLONSEQPlus) for prioritizing treatment options within standard of care guidelines as well as a hot spot cancer panel (50SEQ) by NGS to support treatment options for rare, refractory or recurrent disease. The SEQ testing results associate therapy options based upon FDA, NCCN and ASCO guidelines in a complete and tailored report for the patient and physician.
“Genome-based testing is a more targeted and efficient strategy for physicians to identify and treat mutations that may be driving tumor growth,” said Dr. Raul Benavides, chief medical officer, med fusion. “Our Solid Tumor Program will continue to build upon these strategies that we have implemented for lung and colon cancers. By 2016, med fusion’s solid tumor program will expand to include molecular profiling services for melanoma, glioma, breast and ovarian cancers.”
Aligned with its personalized and comprehensive approaches, med fusion is in network with most private and government insurance providers, and also has available flexible and reflexive molecular profiling algorithms to meet the clinical needs and cost efficiencies for physicians and patients.
“Striving to ensure every patient receives the best health care, we recognize the need to participate in the health plans of our client’s patient population,” states Jon Hart, CEO, med fusion. “As a result, med fusion is a participating provider with most national managed care organizations, as well as, regional and state healthcare insurers. Being a participating provider allows us to offer the most cost efficient testing services to our patients.”